Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
31 /100
COMPONENT-LIMITED
Score updated Aug 28, 2026

HBIO — Harvard Bioscience, Inc. Dilution Risk Tracker

Track HBIO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track HBIO — Get alerts when the score changes →

As of August 28, 2026, Harvard Bioscience, Inc. (HBIO) has a DilutionWatch DilutionScore of 31/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Harvard Bioscience, Inc. has a market capitalization of $26.52M, 4.55M shares outstanding, 8 institutional holders tracked. Stored dilution-related fields include shelf registration capacity of $7.50M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
47
💰Cash Runway
📊 Float Risk
27
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

Watch
Minor dilution signals detected
model est. 10%
💰 Capital Raise model 20%
• Active shelf registration ($8M, 28% of market cap)
🔔 Track HBIO — Get forecast alerts →

Market Data

Market Cap$26.52M
Shares Outstanding4.55M
Float3.53M
Cash$6.50M
Debt$36.68M
Short InterestN/A

Institutional Holdings

QoQ: ↓ 95.7% shares (2026Q1 vs prior)
8 institutional holders · 754.5K shares
#1 BARCLAYS PLC 335.2K shares
#2 Meros Investment Management, LP 118.5K shares
#3 NANO CAP NEW MILLENNIUM GROWTH FUND L P 117.5K shares
+ 5 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest61.4K
Days to Cover5.3
% of Float1.7%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
4 INSIDER TRANSACTION 2026-03-23
4 INSIDER TRANSACTION 2026-03-18
4 INSIDER TRANSACTION 2026-03-18
4 INSIDER TRANSACTION 2026-03-17
Full SEC filing analysis available with free account

Recent News

No recent news

Factual HBIO Dilution Snapshot

Harvard Bioscience, Inc. (HBIO) has a DilutionScore of 31/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track HBIO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking HBIO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for HBIO
HBIO FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.